Jesper Stentoft

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Andreas Hochhaus, Tamás Masszi, Francis J. Giles et al. · Leukemia · 2017 · 286 citations · Full text

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Bengt Simonsson, Tobias Gedde‐Dahl, Berit Markevärn et al. · Blood · 2011 · 194 citations · Full text

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Rebecca Warfvinge, Linda Geironson, Mikael N.E. Sommarin et al. · Blood · 2017 · 175 citations · Full text

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

David M. Ross, Tamás Masszi, María Teresa Gómez‐Casares et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 140 citations · Full text

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

Jerald P. Radich, Andreas Hochhaus, Tamás Masszi et al. · Leukemia · 2021 · 77 citations · Full text